Cargando…

Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients

Functional toll-like receptors (TLRs) could modulate anti-tumor effects by activating inflammatory cytokines and the cytotoxic T-cells response. However, excessive TLR expression could promote tumor progression, since TLR-induced inflammation might stimulate cancer cells expansion into the microenvi...

Descripción completa

Detalles Bibliográficos
Autores principales: Skorka, Katarzyna, Wlasiuk, Paulina, Karczmarczyk, Agnieszka, Giannopoulos, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922273/
https://www.ncbi.nlm.nih.gov/pubmed/33669782
http://dx.doi.org/10.3390/jcm10040867
_version_ 1783658650821197824
author Skorka, Katarzyna
Wlasiuk, Paulina
Karczmarczyk, Agnieszka
Giannopoulos, Krzysztof
author_facet Skorka, Katarzyna
Wlasiuk, Paulina
Karczmarczyk, Agnieszka
Giannopoulos, Krzysztof
author_sort Skorka, Katarzyna
collection PubMed
description Functional toll-like receptors (TLRs) could modulate anti-tumor effects by activating inflammatory cytokines and the cytotoxic T-cells response. However, excessive TLR expression could promote tumor progression, since TLR-induced inflammation might stimulate cancer cells expansion into the microenvironment. Myd88 is involved in activation NF-κB through TLRs downstream signaling, hence in the current study we provided, for the first time, a complex characterization of expression of TLR2, TLR4, TLR7, TLR9, and MYD88 as well as their splicing forms in two distinct compartments of the microenvironment of chronic lymphocytic leukemia (CLL): peripheral blood and bone marrow. We found correlations between MYD88 and TLRs expressions in both compartments, indicating their relevant cooperation in CLL. The MYD88 expression was higher in CLL patients compared to healthy volunteers (HVs) (0.1780 vs. 0.128, p < 0.0001). The TLRs expression was aberrant in CLL compared to HVs. Analysis of survival curves revealed a shorter time to first treatment in the group of patients with low level of TLR4(3) expression compared to high level of TLR4(3) expression in bone marrow (13 months vs. 48 months, p = 0.0207). We suggest that TLRs expression is differentially regulated in CLL but is similarly shared between two distinct compartments of the microenvironment.
format Online
Article
Text
id pubmed-7922273
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79222732021-03-03 Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients Skorka, Katarzyna Wlasiuk, Paulina Karczmarczyk, Agnieszka Giannopoulos, Krzysztof J Clin Med Article Functional toll-like receptors (TLRs) could modulate anti-tumor effects by activating inflammatory cytokines and the cytotoxic T-cells response. However, excessive TLR expression could promote tumor progression, since TLR-induced inflammation might stimulate cancer cells expansion into the microenvironment. Myd88 is involved in activation NF-κB through TLRs downstream signaling, hence in the current study we provided, for the first time, a complex characterization of expression of TLR2, TLR4, TLR7, TLR9, and MYD88 as well as their splicing forms in two distinct compartments of the microenvironment of chronic lymphocytic leukemia (CLL): peripheral blood and bone marrow. We found correlations between MYD88 and TLRs expressions in both compartments, indicating their relevant cooperation in CLL. The MYD88 expression was higher in CLL patients compared to healthy volunteers (HVs) (0.1780 vs. 0.128, p < 0.0001). The TLRs expression was aberrant in CLL compared to HVs. Analysis of survival curves revealed a shorter time to first treatment in the group of patients with low level of TLR4(3) expression compared to high level of TLR4(3) expression in bone marrow (13 months vs. 48 months, p = 0.0207). We suggest that TLRs expression is differentially regulated in CLL but is similarly shared between two distinct compartments of the microenvironment. MDPI 2021-02-19 /pmc/articles/PMC7922273/ /pubmed/33669782 http://dx.doi.org/10.3390/jcm10040867 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Skorka, Katarzyna
Wlasiuk, Paulina
Karczmarczyk, Agnieszka
Giannopoulos, Krzysztof
Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients
title Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients
title_full Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients
title_fullStr Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients
title_full_unstemmed Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients
title_short Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients
title_sort aberrant expression of tlr2, tlr7, tlr9, splicing variants of tlr4 and myd88 in chronic lymphocytic leukemia patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922273/
https://www.ncbi.nlm.nih.gov/pubmed/33669782
http://dx.doi.org/10.3390/jcm10040867
work_keys_str_mv AT skorkakatarzyna aberrantexpressionoftlr2tlr7tlr9splicingvariantsoftlr4andmyd88inchroniclymphocyticleukemiapatients
AT wlasiukpaulina aberrantexpressionoftlr2tlr7tlr9splicingvariantsoftlr4andmyd88inchroniclymphocyticleukemiapatients
AT karczmarczykagnieszka aberrantexpressionoftlr2tlr7tlr9splicingvariantsoftlr4andmyd88inchroniclymphocyticleukemiapatients
AT giannopouloskrzysztof aberrantexpressionoftlr2tlr7tlr9splicingvariantsoftlr4andmyd88inchroniclymphocyticleukemiapatients